PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34329582-3	2022	Compared with the other PARPis rucaparib, olaparib, and niraparib, talazoparib displays the highest potency across SCLC, including SLFN11-negative cells.	talazoparib	67-78	schlafen family member 11	Homo sapiens	131-137	
33536335-4	2021	Accordingly, we validate that clinical inhibitors of ATR (M4344 and M6620) and CHK1 (SRA737) resensitize SLFN11-KO cells to topotecan, indotecan, etoposide, cisplatin, and talazoparib.	talazoparib	172-183	schlafen family member 11	Homo sapiens	105-111	
27440269-10	2017	We confirmed these findings in vivo across multiple PDX and defined IHC staining for SLFN11 as a predictor of talazoparib response.	talazoparib	110-121	schlafen family member 11	Homo sapiens	85-91	
27708213-3	2016	Our genomic analyses reveal high correlation between response to talazoparib and Schlafen 11 (SLFN11) expression.	talazoparib	65-76	schlafen family member 11	Homo sapiens	81-92	
27708213-3	2016	Our genomic analyses reveal high correlation between response to talazoparib and Schlafen 11 (SLFN11) expression.	talazoparib	65-76	schlafen family member 11	Homo sapiens	94-100	
27708213-5	2016	Response to the talazoparib-temozolomide combination was also driven by SLFN11 and validated in 36 small cell lung cancer cell lines, and in xenograft models.	talazoparib	16-27	schlafen family member 11	Homo sapiens	72-78